SOLACEA-H in Heparin-sparing Haemodialysis
The aim of the study is to evaluate the efficacy of the SOLACEA-H dialyser, particularly in patients at high risk of haemorrhage, during post-dilution haemodiafiltration sessions with complete or partial heparin sparing. It will be compared with another dialyser (HYDROLINK-NVU)
- EligibilityCriteria: Inclusion Criteria:  On haemodialysis for at least 3 months Dialysis in a haemodialysis department of the Ramsay-Santé group No active infection Medically stable Blood flow ≥ 300 ml/min Haemoglobin level stable and within recommended norms for a dialysis patient, id est > 10g/dl Bipunction No known allergy to SOLACEA H or HYDROLINK-NVU Willingness to comply with study procedures for the duration of the study For women of childbearing age: effective contraception, or absence of active pregnancy (negative pregnancy test) Member or beneficiary of a social security scheme Patient having been informed and having signed an informed consent form  Exclusion Criteria:  Patient on oral anticoagulants for the duration of the study Patient on dialysate for the duration of the study Patient Medically unstable or fragile Severe hepatic impairment Patient hospitalised without consent Concurrent participation in another clinical study Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision Pregnant, breast-feeding or parturient women Patient unable to receive heparin Known allergy to latex or phthalates - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult